Renalka in UTI in Traumatic Paraplegia Patients

A placebo controlled clinical trial was conducted to evaluate the efficacy of a herbal urinary alkalizer known as Renalka in bacteriologically proven urinary tract infections. One hundred patients of either sex aged between 20-60 years were included in the trial. They were administered Renalka syrup or identically similar placebo syrup at a dose of 2 teaspoonfuls twice daily for 6 weeks. All the patients simultaneously received appropriate oral antibiotics. Twelve patients who had acidic urine were treated with Renalka syrup and at the end of 6 weeks, 10 patients had alkaline urine. In the placebo group 31 patients had acidic urine and at the end of 6 weeks 30 patients continued to have acidic urine. Forty eight patients urine culture was positive for bacteria, at the end of the treatment period and 42 patients were culture negative. In the placebo group 42 patients had bacteriuria before treatment and after treatment only 18 patients were culture negative. Urine microscopy also showed a significant reduction of pus cells after taking Renalka syrup, while many of the patients continued to have pus cells in the urine belonging to the placebo group. Twenty one patients who had typical urinary tract infection symptoms were treated with Renalka and after treatment except for 1 who had increased frequency of urine, all the patients were totally free from the symptoms of urinary tract infections. All the patients in the placebo group had symptoms and after treatment 6 patients continued to suffer from urinary tract infection symptoms. These results indicate that Renalka can be a useful adjuvant in treating urinary tract infections. There were no untoward incidents in both the groups of patients.